Condition
Anemia in Myelodysplastic Syndromes
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting1
Terminated1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07052006Phase 2Active Not Recruiting
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
NCT04623996Phase 1TerminatedPrimary
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
NCT00437450Phase 2UnknownPrimary
Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid
Showing all 3 trials